Skip to search formSkip to main contentSkip to account menu

TLR7/8/9 Antagonist IMO-8400

Known as: IMO-8400, Oligonucleotide IMO-8400 
An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Anti-MYD88… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis
Background Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by an auto-inflammatory immune response… 
Review
2015
Review
2015
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
Introduction: Waldenstrom9s macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by lymphoplasmacytic cell… 
2012
2012
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice (119.12)
Several studies have implicated Toll-like receptors (TLRs) 7, 8 and 9 in the development and progression of lupus. We have… 
2012
2012
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in mouse models of psoriasis (119.8)
Toll-like receptors (TLR) are involved in the pathogenesis of numerous autoimmune diseases, including psoriasis. The role of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)